Blocking aldosterone or its receptor-what is the difference?
- PMID: 38109915
- DOI: 10.1016/S0140-6736(23)02542-4
Blocking aldosterone or its receptor-what is the difference?
Conflict of interest statement
I declare funding support from the US National Institutes of Health (grant number R01HL126903) and Veterans Administration (grant number I01CX001753). I served as a member of the executive steering committees of the FIDELIO and FIGARO trials, continue to serve on the steering committee of the FIND-CKD and CONFIDENCE trials, and am the principal investigator for the CONFIDENCE trial, all funded by Bayer. I serve as a consultant for Bayer, Covance, and Boehringer Ingelheim and have consulted on aldosterone synthase inhibitors for Boehringer Ingelheim but I was not involved with the Article I have commented on here in any capacity. I served on the executive steering committees for Akebia for their HIF-PHI trials and as a consultant. I chair adjudication committees for Alnylam and Intercept Pharma and data safety monitoring boards for Chinook, Vertex, and Eloxx. I receive royalties from UpToDate.
Comment on
-
Efficacy and safety of aldosterone synthase inhibition with and without empagliflozin for chronic kidney disease: a randomised, controlled, phase 2 trial.Lancet. 2024 Jan 27;403(10424):379-390. doi: 10.1016/S0140-6736(23)02408-X. Epub 2023 Dec 15. Lancet. 2024. PMID: 38109916 Clinical Trial.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources